biostudies-literatureSlingluff CLNCRR NIH HHSNCI NIH HHS2924-32https://www.ebi.ac.uk/biostudies/studies/S-EPMC3138719biostudies-literatureUnknown29(21)<h4>Purpose</h4>This multicenter randomized trial was designed to test whether melanoma-associated helper peptides augment CD8(+) T-cell responses to a melanoma vaccine and whether cyclophosphamide (CY) pretreatment augments CD4(+) or CD8(+) T-cell responses to that vaccine.<h4>Patients and methods</h4>In all, 167 eligible patients with resected stage IIB to IV melanoma were randomly assigned to four vaccination study arms. Patients were vaccinated with 12 class I major histocompatibility complex-restricted melanoma peptides (12MP) to stimulate CD8(+) T cells and were randomly assigned to receive a tetanus helper peptide or a mixture of six melanoma-associated helper peptides (6MHP) to stimulate CD4(+) T cells. Before vaccination, patients were also randomly assigned to receive CY pretreatJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.PMC3138719M01 RR000847P30 CA44579R01 CA118386M01 RR00847P30 CA044579von Mehren MChianese-Bullock KASmolkin MEHaas NBRoss MIPetroni GRSlingluff CLGrosh WWfalseRandomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.<h4>Purpose</h4>This multicenter randomized trial was designed to test whether melanoma-associated helper peptides augment CD8(+) T-cell responses to a melanoma vaccine and whether cyclophosphamide (CY) pretreatment augments CD4(+) or CD8(+) T-cell responses to that vaccine.<h4>Patients and methods</h4>In all, 167 eligible patients with resected stage IIB to IV melanoma were randomly assigned to four vaccination study arms. Patients were vaccinated with 12 class I major histocompatibility complex-restricted melanoma peptides (12MP) to stimulate CD8(+) T cells and were randomly assigned to receive a tetanus helper peptide or a mixture of six melanoma-associated helper peptides (6MHP) to stimulate CD4(+) T cells. Before vaccination, patients were also randomly assigned to receive CY pretreat2011-01-01T00:00:00Z2011 Jul2026-05-04T18:39:02.455Z2019-03-26T23:49:33ZS-EPMC31387192169047510.1200/jco.2010.33.805310.1200/JCO.2010.33.8053